Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT. But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders.

PSMA PET imaging’s proliferation produces uptick in aggressive treatment for prostate cancer
First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer.
Bill Gates-backed company breaks ground on 'world's most advanced' isotope production facility
Leaders involved in the new facility’s development estimate it will increase global Ac-225 production capacity twentyfold.
New Mexico company sets sights on bolstering the domestic supply of Mo-99
Eden Radioisotopes believes the facility will have the capacity to produce up to 50% of the global demand for Mo-99 once completed.
Patients in rural communities struggle to access newer tumor-targeting radiotracers
In some cases, patients in isolated areas must travel up to 130 miles to gain access to the latest class of NETs, new data suggest.
Investigational radiotracer has 'extremely valuable' potential for treating chronic condition
New findings suggest that 99mTc-maraciclatide can help physicians more accurately identify endometriosis on imaging.

PSMA PET imaging’s proliferation produces uptick in aggressive treatment for prostate cancer

First approved by the FDA in 2021, providers have rapidly adopted this clinical innovation, which offers greater accuracy in detecting prostate cancer.

TerraPower breaks ground on world's largest isotope production facility

Bill Gates-backed company breaks ground on 'world's most advanced' isotope production facility

Leaders involved in the new facility’s development estimate it will increase global Ac-225 production capacity twentyfold.

New Mexico company sets sights on bolstering the domestic supply of Mo-99

Eden Radioisotopes believes the facility will have the capacity to produce up to 50% of the global demand for Mo-99 once completed.

Patients in rural communities struggle to access newer tumor-targeting radiotracers

In some cases, patients in isolated areas must travel up to 130 miles to gain access to the latest class of NETs, new data suggest.

Endometriosis radiotracer performs well at clinical trial

Investigational radiotracer has 'extremely valuable' potential for treating chronic condition

New findings suggest that 99mTc-maraciclatide can help physicians more accurately identify endometriosis on imaging.

Radiopharmaceutical manufacturer secures $30M to bolster domestic isotope production

Although the company is already bringing in revenue from medical radioisotopes, the new funding will help further these initiatives and drive additional research and development.

FDA accepts previously rejected application for new PET imaging agent

Radiopharma firm Telix hopes to soon begin selling Pixclara (Floretyrosine F 18), an investigational product for glioma, a type of brain cancer.

Department of Energy, Shine working on $263M deal to establish Mo-99 supply in US

If approved, the funds would go toward the completion of Chrysalis—Shine's first-of-its-kind medical isotope production facility.